Corcept Therapeutics Inc SEC Filings

Corcept Therapeutics (CORT) Chief Business Officer Gary Charles Robb reported multiple transactions on 08/22/2025. He acquired 5,000 stock options with a $3.88 exercise price that are fully exercisable and result in 5,000 underlying shares upon exercise. On the same date he sold 2,326 shares at $71.27 and had 2,674 shares withheld at ~$71.17 to satisfy exercise price and taxes from a net exercise. Following these transactions Robb directly beneficially owns 13,364 common shares and indirectly holds 11,571 shares in custodial accounts for his children. The filing notes 2,082 unvested restricted shares (grants from 2024–2025) that vest one year after each grant date if conditions are met.

Form 144 for Corcept Therapeutics (CORT) shows a proposed sale of 2,326 common shares acquired by stock option exercise on 08/22/2025, with cash payment the same day. The sale is through Fidelity Brokerage Services LLC on NASDAQ and the reported aggregate market value is $165,774.02. The filing also lists a prior sale on 06/16/2025 of 3,185 shares generating $225,402.45. The issuer’s outstanding shares are reported as 105,371,729. The filer certifies no undisclosed material adverse information is known.

On 08/11/2025, Daniel N. Swisher Jr., a director of Corcept Therapeutics (CORT), exercised stock options and sold the resulting shares under a pre-established plan. He exercised options with a $14.08 exercise price to acquire 2,200 common shares and sold 2,200 shares at $72.30, leaving him with 0 direct common shares following the transactions. The trades were executed pursuant to a 10b5-1 plan adopted August 1, 2024. After the transactions he retains beneficial ownership of 5,500 stock options that are reported as fully exercisable.

William Guyer, Chief Development Officer of Corcept Therapeutics (CORT) reported insider transactions dated 08/08/2025. The Form 4 shows derivative and non-derivative activity executed pursuant to a 10b5-1 plan adopted on 11/27/2024. The filing reports acquisition in Table II of a stock option granting the right to buy 35,007 shares with an exercise price of $21.65; that option is shown as fully exercisable and carries an expiration date of 09/01/2031. Table II lists 350,000 derivative securities beneficially owned following the reported transaction.

Table I records non-derivative movements on the same date, including a reported disposition coded S of 35,007 common shares at a price of $71.77. The two Table I lines display reported beneficial ownership amounts of 40,494 and 5,487 shares respectively after the reported transactions. The Form notes the 10b5-1 plan governed the transactions.

Corcept Therapeutics (CORT) filed a Form 144 reporting an intended sale of 2,200 common shares through Fidelity on NASDAQ with an aggregate market value of $159,060. The filing lists total shares outstanding of 105,371,729, showing the proposed block represents a very small fraction of outstanding stock.

The securities are shown as acquired in connection with an option granted 08/20/2018 and the filing indicates acquisition and proposed sale activity on 08/11/2025 for cash. The filer, Daniel Swisher, also reported three prior sales in the past three months (2,200 shares each on 05/12/2025, 06/10/2025 and 07/10/2025) with listed gross proceeds for each sale.

On 08/05/2025, Corcept Therapeutics (CORT) Chief Development Officer William Guyer filed a Form 4 detailing a tiny, Rule 10b5-1-planned transaction. He exercised 14 stock options at an exercise price of $21.65 (code M) and immediately sold the same 14 common shares at $71.77 (code S). After the trades, Guyer directly holds 5,487 common shares and still owns 385,007 unexercised options expiring 09/01/2031.

The gross sale proceeds are roughly $1,000, an amount immaterial relative to Corcept’s market cap and Guyer’s remaining equity stake. No other insider activity or company developments are disclosed. Given the de-minimis size and pre-arranged nature, the filing is unlikely to influence investor sentiment or signal a change in management’s outlook.

Corcept Therapeutics (CORT) – Form 4 filing, 08/05/2025: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,823 employee stock options at an exercise price of $13.56 (cost ≈ $79k) and immediately sold the same 5,823 shares under a pre-arranged 10b5-1 plan at a weighted-average $67.5129, generating gross proceeds of ≈ $393k and a spread of ≈ $314k before taxes.

Following the transactions Lyon directly owns 10,066 CORT common shares, including 1,552 unvested RSAs that vest one year from their respective grant dates, and retains 31,571 vested options. No other classes of securities were affected. The transaction neither alters total shares outstanding nor signals corporate fundamentals, but it represents a partial monetisation by a senior officer at ~5× the option strike.